Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

The Lancet

Volumn 396, Issue 10244, 2020, Pages 121-128

  Vaduganathan, Muthiah ^a   Claggett, Brian L ^a   Jhund, Pardeep S ^b   Cunningham, Jonathan W ^a   Pedro Ferreira, João ^c,d   Zannad, Faiez ^c   Packer, Milton ^e,f   Fonarow, Gregg C ^g   McMurray, John J V ^b   Solomon, Scott D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY OF PORTO   (Portugal)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; PLACEBO; SACUBITRIL PLUS VALSARTAN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; EVENT FREE SURVIVAL; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DRUG EFFECT; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEATH; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGRESSION-FREE SURVIVAL; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 85085760213     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)30748-0     Document Type: Article

References (27)

1. Shah, KS, Xu, H, Matsouaka, RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 70 (2017), 2476–2486.
2. Alter, DA, Ko, DT, Tu, JV, et al. The average lifespan of patients discharged from hospital with heart failure. J Gen Intern Med 27 (2012), 1171–1179.
3. Greene, SJ, Butler, J, Albert, NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72 (2018), 351–366.
4. Komajda, M, Schöpe, J, Wagenpfeil, S, et al. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21 (2019), 921–929.
5. Brunner-La Rocca, HP, Linssen, GC, Smeele, FJ, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Hear Fail 7 (2019), 13–21.
6. Zannad, F, McMurray, JJV, Krum, H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
7. Pitt, B, Zannad, F, Remme, WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999), 709–717.
8. McMurray, JJV, Solomon, SD, Inzucchi, SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 (2019), 1995–2008.
9. McMurray, JJVV, Packer, M, Desai, AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
10. Vaduganathan, M, Fonarow, GC, Greene, SJ, et al. Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry. JACC Heart Fail, 2020 published online May 6. DOI:10.1016/j.jchf.2019.12.015.
11. Greene, SJ, Fonarow, GC, DeVore, AD, et al. Longitudinal titration of medical therapy for heart failure with reduced ejection fraction: CHAMP-HF registry. J Am Coll Cardiol 73 (2019), 2365–2383.
12. Tsao, CW, Lyass, A, Enserro, D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6 (2018), 678–685.
13. Vaduganathan, M, Jhund, PS, Claggett, BL, et al. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J, 2020 published online March 28. DOI:10.1093/eurheartj/ehaa184.
14. Fisher, LD, Gent, M, Büller, HR, Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 141 (2001), 26–32.
15. Durrleman, S, Chaikin, P, The use of putative placebo in active control trials: two applications in a regulatory setting. Stat Med 22 (2003), 941–952.
16. Hasselblad, V, Kong, DF, Statistical methods for comparison to placebo in active-control trials. Drug Inform J 35 (2001), 435–449.
17. McMurray, J, Packer, M, Desai, A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 36 (2015), 434–439.
18. Claggett, B, Packer, M, McMurray, JJV, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med 373 (2015), 2289–2290.
19. Stienen, S, Ferreira, JP, Vincent, J, et al. Estimated long-term survival with eplerenone. J Am Coll Cardiol 73 (2019), 2357–2359.
20. Ferreira, JP, Rossello, X, Eschalier, R, et al. MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC Hear Fail 7 (2019), 1012–1021.
21. Jhund, PS, Fu, M, Bayram, E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 36 (2015), 2576–2584.
22. Martinez, FA, Serenelli, M, Nicolau, JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 141 (2020), 100–111.
23. Burnett, H, Earley, A, Voors, AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Hear Fail, 10, 2017, e003529.
24. Desai, AS, Vardeny, O, Claggett, B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2 (2017), 79–85.
25. Bhagat, AA, Greene, SJ, Vaduganathan, M, Fonarow, GC, Butler, J, Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail 7 (2019), 1–12.
26. Vaduganathan, M, Gheorghiade, M, Butler, J, Expanding the scope of the ‘polypill’ to heart failure. J Card Fail 19 (2013), 540–541.
27. Paladino, J, Lakin, JR, Sanders, JJ, Communication strategies for sharing prognostic information with patients: beyond survival statistics. JAMA, 322, 2019, 1345.